Testosterone Therapy and Its Monitoring in Adolescent Boys with Hypogonadism: Results of an International Survey from the I-DSD Registry
Testosterone Therapy and Its Monitoring in Adolescent Boys with Hypogonadism: Results of an International Survey from the I-DSD Registry
复制标题
患有性腺功能减退症的青春期男孩的睾酮治疗及其监测：I-DSD 登记处的一项国际调查结果
DOI：
10.1159/000516784
复制
发表时间：
2021
影响因子：
2.3
通讯作者：
S. Ahmed
中科院分区：
文献类型：
--
作者：
M. Stancampiano;A. Lucas;J. Bryce;G. Russo;G. Barera;A. Balsamo;F. Baronio;S. Bertelloni;Margherita Valiani;M. Cools;L. Tack;F. Darendeliler;S. Poyrazoglu;E. Globa;Romina P. Grinspon;S. Hannema;I. Hughes;Rieko Tadokoro;A. Thankamony;V. Iotova;V. Mladenov;D. Konrad;I. Mazen;M. Niedziela;Z. Kolesinska;A. Nordenström;S. Ahmed
目前还不清楚睾酮替代疗法（TRT）是否在受一系列可能与性腺功能减退相关的内分泌疾病影响的青春期男孩中特别常见。本研究的目的是评估I-DSD登记处中男孩的TRT当代实践。邀请I-DSD登记研究中所有参与中心的10至18岁男孩以及可能与性腺功能减退症相关的疾病在2019年提供进一步信息。从15个中心收集了162名男孩的信息，每个中心的中位数（范围）为6名男孩（1.35）。其中，来自9个中心的30例（19%）接受TRT，开始时的中位（范围）年龄为12.6岁（10.8-16.2），6例男孩（20%）开始时<12岁。未接受TRT的男孩的中位（范围）年龄为11.7岁（10.7-17.7），132例中有69例（52%）<12岁。71例性腺发育障碍的男孩中有20例（28%）开始TRT，14例雄激素合成障碍的男孩中有3例（21%）开始TRT，所有7例（100%）男孩都患有低促性腺激素性性腺功能减退症。其余未接受TRT的患者包括15名部分雄激素不敏感的男孩，52名非特异性XY DSD，3名持续性苗勒管综合征。在开始TRT之前，分别检查了19例（68%）和18例（64%）男孩的肝功能和血细胞计数，23例（82%）进行了骨龄评估，12例（43%）进行了骨密度评估。当代实践的这一快照显示，I-DSD登记研究中纳入的男孩TRT并不常见，而开始和监测治疗的变化相当明显。实践的标准化可能会导致更有效的评估治疗结果。
It is unclear whether testosterone replacement therapy (TRT) in adolescent boys, affected by a range of endocrine diseases that may be associated with hypogonadism, is particularly common. The aim of this study was to assess the contemporary practice of TRT in boys included in the I-DSD Registry. All participating centres in the I-DSD Registry that had boys between 10 and 18 years of age and with a condition that could be associated with hypogonadism were invited to provide further information in 2019. Information on 162 boys was collected from 15 centres that had a median (range) number of 6 boys per centre (1.35). Of these, 30 (19%) from 9 centres were receiving TRT and the median (range) age at the start was 12.6 years (10.8–16.2), with 6 boys (20%) starting at <12 years. Median (range) age of boys not on TRT was 11.7 years (10.7–17.7), and 69 out of 132 (52%) were <12 years. TRT had been initiated in 20 of 71 (28%) boys with a disorder of gonadal development, 3 of 14 (21%) with a disorder of androgen synthesis, and all 7 (100%) boys with hypogonadotropic hypogonadism. The remainder who did not have TRT included 15 boys with partial androgen insensitivity, 52 with non-specific XY DSD, and 3 with persistent Müllerian duct syndrome. Before starting TRT, liver function and blood count were checked in 19 (68%) and 18 boys (64%), respectively, a bone age assessment was performed in 23 (82%) and bone mineral density assessment in 12 boys (43%). This snapshot of contemporary practice reveals that TRT in boys included in the I-DSD Registry is not very common, whilst the variation in starting and monitoring therapy is quite marked. Standardisation of practice may lead to more effective assessment of treatment outcomes.
DOI：
10.1210/jc.2016-1372
发表时间：
2016-11
期刊：
The Journal of clinical endocrinology and metabolism
影响因子：
--
作者：
Lucas-Herald A;Bertelloni S;Juul A;Bryce J;Jiang J;Rodie M;Sinnott R;Boroujerdi M;Lindhardt Johansen M;Hiort O;Holterhus PM;Cools M;Guaragna-Filho G;Guerra-Junior G;Weintrob N;Hannema S;Drop S;Guran T;Darendeliler F;Nordenstrom A;Hughes IA;Acerini C;Tadokoro-Cuccaro R;Ahmed SF
通讯作者：
Ahmed SF